PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
28412730-10	2017	Relative to the vector control line, there was less cell death in OSU-CLL over-expressing treRNA after exposure to fludarabine and mafosfamide, due in part to a reduction in DNA damage.	mafosfamide	131-142	translation regulatory long non-coding RNA 1	Homo sapiens	90-96
24677340-1	2014	Aldehyde dehydrogenase 3A1 (ALDH3A1) plays an important role in many cellular oxidative processes, including cancer chemoresistance, by metabolizing activated forms of oxazaphosphorine drugs such as cyclophosphamide (CP) and its analogues, such as mafosfamide (MF), ifosfamide (IFM), and 4-hydroperoxycyclophosphamide (4-HPCP).	mafosfamide	248-259	aldehyde dehydrogenase 3 family member A1	Homo sapiens	28-35
23604128-9	2014	Additionally, XPC and DDB2 induction occurred upon treatment with other cross-linking anticancer drugs, such as cisplatin and mafosfamide, indicating it is a general response of cancer cells to this group of chemotherapeutics.	mafosfamide	126-137	xeroderma pigmentosum, complementation group C	Mus musculus	14-17
23604128-9	2014	Additionally, XPC and DDB2 induction occurred upon treatment with other cross-linking anticancer drugs, such as cisplatin and mafosfamide, indicating it is a general response of cancer cells to this group of chemotherapeutics.	mafosfamide	126-137	damage specific DNA binding protein 2	Mus musculus	22-26
24677340-1	2014	Aldehyde dehydrogenase 3A1 (ALDH3A1) plays an important role in many cellular oxidative processes, including cancer chemoresistance, by metabolizing activated forms of oxazaphosphorine drugs such as cyclophosphamide (CP) and its analogues, such as mafosfamide (MF), ifosfamide (IFM), and 4-hydroperoxycyclophosphamide (4-HPCP).	mafosfamide	248-259	aldehyde dehydrogenase 3 family member A1	Homo sapiens	0-26
24677340-1	2014	Aldehyde dehydrogenase 3A1 (ALDH3A1) plays an important role in many cellular oxidative processes, including cancer chemoresistance, by metabolizing activated forms of oxazaphosphorine drugs such as cyclophosphamide (CP) and its analogues, such as mafosfamide (MF), ifosfamide (IFM), and 4-hydroperoxycyclophosphamide (4-HPCP).	mafosfamide	261-263	aldehyde dehydrogenase 3 family member A1	Homo sapiens	0-26
24677340-1	2014	Aldehyde dehydrogenase 3A1 (ALDH3A1) plays an important role in many cellular oxidative processes, including cancer chemoresistance, by metabolizing activated forms of oxazaphosphorine drugs such as cyclophosphamide (CP) and its analogues, such as mafosfamide (MF), ifosfamide (IFM), and 4-hydroperoxycyclophosphamide (4-HPCP).	mafosfamide	261-263	aldehyde dehydrogenase 3 family member A1	Homo sapiens	28-35
15735131-12	2005	Ventricular CSF mafosfamide concentrations at 5 mg exceeded target cytotoxic concentrations after an intraventricular dose, but lumbar CSF concentrations 2 hours after the dose were less than 10 micromol/L.	mafosfamide	16-27	colony stimulating factor 2	Homo sapiens	12-15
24387105-0	2014	Selective ALDH3A1 inhibition by benzimidazole analogues increase mafosfamide sensitivity in cancer cells.	mafosfamide	65-76	aldehyde dehydrogenase 3 family member A1	Homo sapiens	10-17
24387105-8	2014	ALDH3A1-expressing lung adenocarcinoma and glioblastoma cell lines are sensitized toward mafosfamide (MF) treatment in the presence analogues of CB7, whereas primary lung fibroblasts lacking ALDH3A1 expression, are not.	mafosfamide	89-100	aldehyde dehydrogenase 3 family member A1	Homo sapiens	0-7
24387105-8	2014	ALDH3A1-expressing lung adenocarcinoma and glioblastoma cell lines are sensitized toward mafosfamide (MF) treatment in the presence analogues of CB7, whereas primary lung fibroblasts lacking ALDH3A1 expression, are not.	mafosfamide	102-104	aldehyde dehydrogenase 3 family member A1	Homo sapiens	0-7
23948971-8	2013	Moreover, combining fludarabine or mafosfamide with the anti-CD62L in vitro produced an additive effect both with and without stromal cells.	mafosfamide	35-46	selectin L	Homo sapiens	61-66
23185784-0	2012	Modulation of IL-10/IL-10R expression by mafosfamide, a derivative of 4-hydroxycyclophosphamide, in a rat B-cell lymphoma.	mafosfamide	41-52	interleukin 10	Rattus norvegicus	14-19
23185784-6	2012	Mafosfamide induced down-regulation of IL-10 production and IL-10R expression on metastatic cells and, concomitantly, inhibited metastatic cell proliferation.	mafosfamide	0-11	interleukin 10	Rattus norvegicus	39-44
23185784-7	2012	We suggest that mafosfamide would inhibit the regulatory loop mediated by the IL-10/IL-10R system and, as a consequence, metastatic cell proliferation.	mafosfamide	16-27	interleukin 10	Rattus norvegicus	78-83
22753761-0	2012	TRAIL and taurolidine enhance the anticancer activity of doxorubicin, trabectedin and mafosfamide in HT1080 human fibrosarcoma cells.	mafosfamide	86-97	TNF superfamily member 10	Homo sapiens	0-5
20642818-1	2010	BACKGROUND: According to the different sensitivity of their bone marrow CD34+ cells to in vitro treatment with Etoposide or Mafosfamide, Acute Myeloid Leukaemia (AML) patients in apparent complete remission (CR) after chemotherapy induction may be classified into three groups: (i) normally responsive; (ii) chemoresistant; (iii) highly chemosensitive.	mafosfamide	124-135	CD34 molecule	Homo sapiens	72-76
18289623-0	2008	Apoptotic death induced by the cyclophosphamide analogue mafosfamide in human lymphoblastoid cells: contribution of DNA replication, transcription inhibition and Chk/p53 signaling.	mafosfamide	57-68	megakaryocyte-associated tyrosine kinase	Homo sapiens	162-165
18289623-0	2008	Apoptotic death induced by the cyclophosphamide analogue mafosfamide in human lymphoblastoid cells: contribution of DNA replication, transcription inhibition and Chk/p53 signaling.	mafosfamide	57-68	tumor protein p53	Homo sapiens	166-169
18289623-3	2008	Using the cyclophosphamide analogue mafosfamide, which does not need metabolic activation, we show that mafosfamide induces apoptosis dose and time dependently in lymphoblastoid cells, with clearly more apoptosis in p53(wt) cells.	mafosfamide	104-115	tumor protein p53	Homo sapiens	216-219
18289623-9	2008	Mafosfamide caused p53 stabilization by phosphorylation of Ser15, 20 and 37, and activation of ATM/ATR and Chk1/Chk2.	mafosfamide	0-11	tumor protein p53	Homo sapiens	19-22
18289623-9	2008	Mafosfamide caused p53 stabilization by phosphorylation of Ser15, 20 and 37, and activation of ATM/ATR and Chk1/Chk2.	mafosfamide	0-11	ATM serine/threonine kinase	Homo sapiens	95-98
18289623-9	2008	Mafosfamide caused p53 stabilization by phosphorylation of Ser15, 20 and 37, and activation of ATM/ATR and Chk1/Chk2.	mafosfamide	0-11	ATR serine/threonine kinase	Homo sapiens	99-102
18289623-9	2008	Mafosfamide caused p53 stabilization by phosphorylation of Ser15, 20 and 37, and activation of ATM/ATR and Chk1/Chk2.	mafosfamide	0-11	checkpoint kinase 1	Homo sapiens	107-111
16298473-0	2006	Xrcc2 deficiency sensitizes cells to apoptosis by MNNG and the alkylating anticancer drugs temozolomide, fotemustine and mafosfamide.	mafosfamide	121-132	X-ray repair complementing defective repair in Chinese hamster cells 2	Mus musculus	0-5
16298473-10	2006	Xrcc2 deficient cells were found to be hypersensitive to temozolomide, fotemustine and mafosfamide.	mafosfamide	87-98	X-ray repair complementing defective repair in Chinese hamster cells 2	Mus musculus	0-5
16435011-5	2006	Treatment with 1.0 microM imatinib, 60 microg/ml mafosfamide and 14 days of culture with cytokines eliminated BCR-ABL(+) cells from chronic phase CML patient aphereses, while preserving normal progenitors.	mafosfamide	49-60	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	110-117
23430607-5	2013	Our findings suggest that Stx1 could be used to improve the mafosfamide-mediated purging of Gb3Cer/CD77+ tumor cells before autologous bone marrow transplantation.	mafosfamide	60-71	alpha 1,4-galactosyltransferase (P blood group)	Homo sapiens	99-103
22753738-1	2012	Mafosfamide (4-thioethane sulfonic acid salt of 4-hydroxy-cyclophosphamide, MAF) belongs to a new generation of the oxazaphosphorine agents.	mafosfamide	0-11	MAF bZIP transcription factor	Homo sapiens	76-79
18289623-9	2008	Mafosfamide caused p53 stabilization by phosphorylation of Ser15, 20 and 37, and activation of ATM/ATR and Chk1/Chk2.	mafosfamide	0-11	checkpoint kinase 2	Homo sapiens	112-116
17089066-3	2006	All drugs used alone, and cladribine combinations with mafosfamide and/or mitoxantrone induced DNA fragmentation and the changes in expression/proteolysis level of caspase-3, caspase-9 precursors, PARP-1, lamin B, Bax and Bcl-2; however, each to a different degree.	mafosfamide	55-66	caspase 3	Homo sapiens	164-173
17089066-3	2006	All drugs used alone, and cladribine combinations with mafosfamide and/or mitoxantrone induced DNA fragmentation and the changes in expression/proteolysis level of caspase-3, caspase-9 precursors, PARP-1, lamin B, Bax and Bcl-2; however, each to a different degree.	mafosfamide	55-66	caspase 9	Homo sapiens	175-184
17089066-3	2006	All drugs used alone, and cladribine combinations with mafosfamide and/or mitoxantrone induced DNA fragmentation and the changes in expression/proteolysis level of caspase-3, caspase-9 precursors, PARP-1, lamin B, Bax and Bcl-2; however, each to a different degree.	mafosfamide	55-66	BCL2 associated X, apoptosis regulator	Homo sapiens	214-217
17089066-3	2006	All drugs used alone, and cladribine combinations with mafosfamide and/or mitoxantrone induced DNA fragmentation and the changes in expression/proteolysis level of caspase-3, caspase-9 precursors, PARP-1, lamin B, Bax and Bcl-2; however, each to a different degree.	mafosfamide	55-66	BCL2 apoptosis regulator	Homo sapiens	222-227
11723234-4	2001	CPA and MFA were both shown to effect tumor cell death by stimulating apoptosis, as evidenced by the induction of plasma membrane blebbing, DNA fragmentation, and cleavage of the caspase 3 and caspase 7 substrate poly(ADP-ribose) polymerase (PARP) in drug-treated cells.	mafosfamide	8-11	caspase 3	Homo sapiens	179-188
11723234-4	2001	CPA and MFA were both shown to effect tumor cell death by stimulating apoptosis, as evidenced by the induction of plasma membrane blebbing, DNA fragmentation, and cleavage of the caspase 3 and caspase 7 substrate poly(ADP-ribose) polymerase (PARP) in drug-treated cells.	mafosfamide	8-11	caspase 7	Homo sapiens	193-202
11723234-4	2001	CPA and MFA were both shown to effect tumor cell death by stimulating apoptosis, as evidenced by the induction of plasma membrane blebbing, DNA fragmentation, and cleavage of the caspase 3 and caspase 7 substrate poly(ADP-ribose) polymerase (PARP) in drug-treated cells.	mafosfamide	8-11	poly(ADP-ribose) polymerase 1	Homo sapiens	213-240
11723234-4	2001	CPA and MFA were both shown to effect tumor cell death by stimulating apoptosis, as evidenced by the induction of plasma membrane blebbing, DNA fragmentation, and cleavage of the caspase 3 and caspase 7 substrate poly(ADP-ribose) polymerase (PARP) in drug-treated cells.	mafosfamide	8-11	poly(ADP-ribose) polymerase 1	Homo sapiens	242-246
11723234-5	2001	Caspase 9 was identified as the regulatory upstream caspase activated in 9L cells treated with CPA, MFA, or 4OOH-IFA, implicating the mitochondrial apoptotic pathway in oxazaphosphorine-induced tumor cell death.	mafosfamide	100-103	caspase 9	Homo sapiens	0-9
10197801-0	1999	The cytotoxicity of mafosfamide on G-CSF mobilized hematopoietic progenitors is reduced by SH groups of albumin--implications for further purging strategies.	mafosfamide	20-31	colony stimulating factor 3	Homo sapiens	35-40
11798504-0	2001	Ex vivo expansion of normal progenitor cells from acute myeloid leukemia cell-contaminated CD34+ peripheral blood progenitor cells after mafosfamide purging.	mafosfamide	137-148	CD34 molecule	Homo sapiens	91-95
11237055-3	2001	We tested whether combinations of STI571 and cytarabine or other chemotherapeutic agents such as hydroxyurea, mafosfamide or etoposide would display synergistic activity in BCR-ABL-positive chronic myelogenous leukemia (CML) cell lines derived from patients in blast crisis.	mafosfamide	110-121	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	177-180
11306049-1	2001	ALDH3A1 catalyzes the detoxification of cyclophosphamide, mafosfamide, 4-hydroperoxycyclophosphamide and other oxazaphosphorines.	mafosfamide	58-69	aldehyde dehydrogenase 3 family member A1	Homo sapiens	0-7
10856427-5	2000	hALDH3 activity was 0.016 IU/mg protein in the transduced cells (compared with 2x10(-5) IU/mg in untransduced cells), but there was no detectable resistance to aldophosphamide-generating compounds (mafosfamide or 4-hydroperoxycyclophosphamide).	mafosfamide	198-209	aldehyde dehydrogenase 3 family member A1	Homo sapiens	0-6
10808203-0	2000	Purging of G-CSF-mobilized peripheral autografts in acute leukemia with mafosfamide and amifostine to protect normal progenitor cells.	mafosfamide	72-83	colony stimulating factor 3	Homo sapiens	11-16
10782892-7	2000	Also, pentoxifylline increased resistance of the MOR cell lines to mafosfamide.	mafosfamide	67-78	opioid receptor mu 1	Homo sapiens	49-52
10515887-7	1999	Mafosfamide significantly increased the apoptosis induced by fludarabine on CD19(+) cells (P =.007), but not on CD3(+) cells (P =.	mafosfamide	0-11	CD19 molecule	Homo sapiens	76-80
10197801-2	1999	To determine the influence of protein-bound SH groups in the incubation medium, the cytotoxicity of mafosfamide on G-CSF mobilized CD34+/- cells was evaluated by short-term culture assays and drug concentration measurements.	mafosfamide	100-111	colony stimulating factor 3	Homo sapiens	115-120
10197801-2	1999	To determine the influence of protein-bound SH groups in the incubation medium, the cytotoxicity of mafosfamide on G-CSF mobilized CD34+/- cells was evaluated by short-term culture assays and drug concentration measurements.	mafosfamide	100-111	CD34 molecule	Homo sapiens	131-135
9447833-7	1997	UCB progenitor cells showed a higher resistance to mafosfamide treatment, in comparison to BM; the addition of SCF to the culture medium resulted in a statistically significant increase in mafosfamide concentration required to inhibit 95% of colony growth (P < or = 0.05).	mafosfamide	51-62	KIT ligand	Homo sapiens	111-114
9776312-6	1998	Increased MRP was also associated with modest resistance to the oxazaphosphorine compounds mafosfamide, 4-hydroxycyclophosphamide, and 4-hydroperoxycyclophosphamide.	mafosfamide	91-102	ATP binding cassette subfamily C member 1	Homo sapiens	10-13
9447833-7	1997	UCB progenitor cells showed a higher resistance to mafosfamide treatment, in comparison to BM; the addition of SCF to the culture medium resulted in a statistically significant increase in mafosfamide concentration required to inhibit 95% of colony growth (P < or = 0.05).	mafosfamide	189-200	KIT ligand	Homo sapiens	111-114
9447833-8	1997	Moreover, as shown by single colony transfer assays, the presence of SCF in primary cultures promoted a significantly higher replating potential for both untreated (42 +/- 3.3% vs 21 +/- 4.6%, P < or = 0.018) and mafosfamide-treated samples (62 +/- 5.6% vs 44 +/- 6.1%, P < or = 0.018).	mafosfamide	216-227	KIT ligand	Homo sapiens	69-72
8662658-6	1996	Expressed ALDH activity was closely correlated (r = 0.99) with resistance to mafosfamide, up to 21-fold relative to controls.	mafosfamide	77-88	aldehyde dehydrogenase 1 family member A1	Homo sapiens	10-14
8998181-12	1997	In addition, cellular uptake of bcr/abl antisense [S]ODNs appeared to be increased twofold to sixfold by prior treatment with mafosfamide.	mafosfamide	126-137	BCR activator of RhoGEF and GTPase	Mus musculus	32-35
8998181-12	1997	In addition, cellular uptake of bcr/abl antisense [S]ODNs appeared to be increased twofold to sixfold by prior treatment with mafosfamide.	mafosfamide	126-137	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	36-39
9131009-13	1997	2) The intracellular GSH levels of unseparated rIL-2 activated lymphocytes were reduced by ifosfamide and mafosfamide at concentrations above 16 microM.	mafosfamide	106-117	interleukin 2	Rattus norvegicus	47-52
8662658-9	1996	Alkaline elution studies showed that expression of ALDH-1 reduced the number of DNA cross-links commensurate with mafosfamide resistance, and this reduction in cross-links was fully reversed by the inhibitor.	mafosfamide	114-125	aldehyde dehydrogenase 1 family member A1	Homo sapiens	51-57
8662659-10	1996	Clones expressing elevated human (386-5938 milliunits/mg) or rat (4-597 milliunits/mg, benzaldehyde/NADP+ substrate) ALDH-3 activity were 1.3- to 12-fold resistant to mafosfamide relative to control cells (<1 milliunit/mg).	mafosfamide	167-178	aldehyde dehydrogenase 3 family, member A1	Rattus norvegicus	117-123
18475635-0	1995	Interleukin-2 receptor beta chain as a possible target for low doses of mafosfamide.	mafosfamide	72-83	interleukin 2 receptor, alpha chain	Mus musculus	0-22
8654195-1	1995	The cytosolic class aldehyde dehydrogenase (ALDH-3) present in human normal tissues/secretions is apparently much less able to catalyze the oxidation aldophosphamide to carboxyphosphamide than is the ALDH-3 present in human tumor cells/tissues, suggesting that the former may be less able to protect cells from the cytotoxic action of cyclophosphamide, mafosfamide, and other oxazaphosphorines.	mafosfamide	353-364	aldehyde dehydrogenase 3 family member A1	Homo sapiens	44-50
8654195-1	1995	The cytosolic class aldehyde dehydrogenase (ALDH-3) present in human normal tissues/secretions is apparently much less able to catalyze the oxidation aldophosphamide to carboxyphosphamide than is the ALDH-3 present in human tumor cells/tissues, suggesting that the former may be less able to protect cells from the cytotoxic action of cyclophosphamide, mafosfamide, and other oxazaphosphorines.	mafosfamide	353-364	aldehyde dehydrogenase 3 family member A1	Homo sapiens	200-206
7887982-1	1995	High-level cytosolic class-3 aldehyde dehydrogenase (ALDH-3)-mediated oxazaphosphorine-specific resistance (> 35-fold as judged by the concentrations of mafosfamide required to effect a 90% cell-kill) was induced in cultured human breast adenocarcinoma MCF-7/0 cells by growing them in the presence of 30 microM catechol for 5 days.	mafosfamide	156-167	aldehyde dehydrogenase 3 family member A1	Homo sapiens	53-59
7670404-5	1995	Even the primitive stem cells treated with very high doses of mafosfamide (2 to 4 times the usually recommended dose) responded to a combination of SCF + GM-CSF + G-CSF + IL-3 in liquid marrow culture, suggesting that they were functionally spared by the treatment.	mafosfamide	62-73	KIT ligand	Homo sapiens	148-151
7670404-5	1995	Even the primitive stem cells treated with very high doses of mafosfamide (2 to 4 times the usually recommended dose) responded to a combination of SCF + GM-CSF + G-CSF + IL-3 in liquid marrow culture, suggesting that they were functionally spared by the treatment.	mafosfamide	62-73	colony stimulating factor 2	Homo sapiens	154-160
7670404-5	1995	Even the primitive stem cells treated with very high doses of mafosfamide (2 to 4 times the usually recommended dose) responded to a combination of SCF + GM-CSF + G-CSF + IL-3 in liquid marrow culture, suggesting that they were functionally spared by the treatment.	mafosfamide	62-73	colony stimulating factor 3	Homo sapiens	163-168
18475635-3	1995	The ability of low doses of mafosfamide (Mf) to affect IL-2-induced CTL proliferation has been demonstrated.	mafosfamide	28-39	interleukin 2	Mus musculus	55-59
8124665-2	1994	Only the human liver cytosolic ALDH preparation (ALDH1) showed any significant oxidation of aldophosphamide and mafosfamide.	mafosfamide	112-123	aldehyde dehydrogenase 1 family member A1	Homo sapiens	31-35
8083225-4	1994	Clonogenic survival assay data indicated that even modest expression of rat class 3 ALDH was associated with resistance (2-4-fold) to the CPA analog mafosfamide and that the fold resistance was directly proportional to the class 3 ALDH activity expressed in clonal transfectants.	mafosfamide	149-160	aldehyde dehydrogenase 3 family, member A1	Rattus norvegicus	84-88
8019464-1	1994	We carried out a pilot study on the use of recombinant human erythropoietin (rHuEPO) in children undergoing allogeneic or mafosfamide-purged autologous BMT for ALL or AML.	mafosfamide	122-133	erythropoietin	Homo sapiens	61-75
7633833-0	1994	Mafosfamide enhances interleukin-2-generated human effector cell cytotoxic activity against K562 myeloid leukaemia cells.	mafosfamide	0-11	interleukin 2	Homo sapiens	21-34
7688839-7	1993	A moderate but significant enhancement of mafosfamide cytotoxicity by HGF was also observed (p < 0.05 at 1.0 microgram/ml mafosfamide by IL-3 and GM-CSF and p < 0.05 at 10 micrograms/ml mafosfamide by GM-CSF).	mafosfamide	42-53	colony stimulating factor 2	Homo sapiens	207-213
7688839-7	1993	A moderate but significant enhancement of mafosfamide cytotoxicity by HGF was also observed (p < 0.05 at 1.0 microgram/ml mafosfamide by IL-3 and GM-CSF and p < 0.05 at 10 micrograms/ml mafosfamide by GM-CSF).	mafosfamide	125-136	hepatocyte growth factor	Homo sapiens	70-73
7688839-7	1993	A moderate but significant enhancement of mafosfamide cytotoxicity by HGF was also observed (p < 0.05 at 1.0 microgram/ml mafosfamide by IL-3 and GM-CSF and p < 0.05 at 10 micrograms/ml mafosfamide by GM-CSF).	mafosfamide	125-136	interleukin 3	Homo sapiens	140-144
8083225-6	1994	The resistance conferred by ALDH to mafosfamide is OAP-specific since the 3A1-31A line is also resistant to 4-hydroperoxycyclophosphamide (2.9-fold) and 4-hydroperoxyifosfamide (3.2-fold) but not to the non-oxazaphosphorine drugs phosphoramide mustard and melphalan, which cannot be detoxified by aldehyde dehydrogenase enzymes.	mafosfamide	36-47	aldehyde dehydrogenase 3 family, member A1	Rattus norvegicus	28-32
8069187-7	1994	Notably, all four cases exhibiting resistance to mafosfamide, i.e., SF20 > or = 0.5, were males with T-lineage ALL.	mafosfamide	49-60	myeloid derived growth factor	Homo sapiens	68-72
7509656-14	1994	The CD34+, stroma-adherent fraction contained 38% +/- 14% (untreated) and 56% +/- 18% (mafosfamide-treated) (P < or = .025) Ph- progenitors.	mafosfamide	87-98	CD34 molecule	Homo sapiens	4-8
8124665-2	1994	Only the human liver cytosolic ALDH preparation (ALDH1) showed any significant oxidation of aldophosphamide and mafosfamide.	mafosfamide	112-123	aldehyde dehydrogenase 1 family member A1	Homo sapiens	49-54
8298560-6	1993	Hence mafo purging appears to be more efficient when done in early CR1 compared with later stages of disease.	mafosfamide	6-10	complement C3b/C4b receptor 1 (Knops blood group)	Homo sapiens	67-70
7688839-7	1993	A moderate but significant enhancement of mafosfamide cytotoxicity by HGF was also observed (p < 0.05 at 1.0 microgram/ml mafosfamide by IL-3 and GM-CSF and p < 0.05 at 10 micrograms/ml mafosfamide by GM-CSF).	mafosfamide	125-136	hepatocyte growth factor	Homo sapiens	70-73
7691323-0	1993	Effect of recombinant human stem cell factor on mafosfamide-treated bone marrow clonogenic cells.	mafosfamide	48-59	KIT ligand	Homo sapiens	28-44
7688839-7	1993	A moderate but significant enhancement of mafosfamide cytotoxicity by HGF was also observed (p < 0.05 at 1.0 microgram/ml mafosfamide by IL-3 and GM-CSF and p < 0.05 at 10 micrograms/ml mafosfamide by GM-CSF).	mafosfamide	125-136	interleukin 3	Homo sapiens	140-144
8352540-0	1993	C-myc expression is down-regulated in mafosfamide-treated HL-60 cells undergoing apoptosis.	mafosfamide	38-49	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	0-5
8352540-2	1993	Since we have previously shown apoptosis to occur in HL-60 leukemic cells exposed to the prodrug Mafosfamide (ASTA Z 7557), the present study was undertaken to examine the levels of c-myc mRNA transcripts in such cells.	mafosfamide	97-108	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	182-187
8352540-5	1993	After 6 and 24 hours of Mafosfamide-exposure, however, there was a dose- and time-dependent decrease in c-myc transcripts.	mafosfamide	24-35	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	104-109
8352540-7	1993	Morphological, biochemical and ultrastructural evidence of apoptosis accompanied the Mafosfamide-induced c-myc mRNA down-regulation at 24 hours.	mafosfamide	85-96	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	105-110
8352540-8	1993	We conclude that, in the context of Mafosfamide-treated HL-60 cells, upregulation of c-myc mRNA transcription was not fundamental for the activation of the apoptotic cascade.	mafosfamide	36-47	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	85-90
7691323-2	1993	It was the aim of the present study to investigate the capability of recombinant human stem cell factor (SCF) in combination with other growth factors to support the in vitro growth of mafosfamide-treated progenitor cells such as mixed colony forming units (CFU-GEMM), erythroid burst forming units (BFU-E) and granulocyte-macrophage CFU (CFU-GM).	mafosfamide	185-196	KIT ligand	Homo sapiens	87-103
7691323-2	1993	It was the aim of the present study to investigate the capability of recombinant human stem cell factor (SCF) in combination with other growth factors to support the in vitro growth of mafosfamide-treated progenitor cells such as mixed colony forming units (CFU-GEMM), erythroid burst forming units (BFU-E) and granulocyte-macrophage CFU (CFU-GM).	mafosfamide	185-196	KIT ligand	Homo sapiens	105-108
7691323-5	1993	SCF induces a dose-dependent, statistically significant enhancement of colony formation by CD34+, mafosfamide-treated cells.	mafosfamide	98-109	KIT ligand	Homo sapiens	0-3
7691323-6	1993	As shown by single colony transfer experiments, mafosfamide-resistant clones promoted by SCF have a significantly higher replating capacity as compared with mafosfamide-resistant clones grown without SCF.	mafosfamide	48-59	KIT ligand	Homo sapiens	89-92
7691323-6	1993	As shown by single colony transfer experiments, mafosfamide-resistant clones promoted by SCF have a significantly higher replating capacity as compared with mafosfamide-resistant clones grown without SCF.	mafosfamide	48-59	KIT ligand	Homo sapiens	200-203
1421413-0	1992	Use of recombinant human granulocyte-macrophage colony-stimulating factor in patients with lymphoid malignancies transplanted with unpurged or adjusted-dose mafosfamide-purged autologous marrow.	mafosfamide	157-168	colony stimulating factor 2	Homo sapiens	25-73
7688839-7	1993	A moderate but significant enhancement of mafosfamide cytotoxicity by HGF was also observed (p < 0.05 at 1.0 microgram/ml mafosfamide by IL-3 and GM-CSF and p < 0.05 at 10 micrograms/ml mafosfamide by GM-CSF).	mafosfamide	42-53	hepatocyte growth factor	Homo sapiens	70-73
7688839-7	1993	A moderate but significant enhancement of mafosfamide cytotoxicity by HGF was also observed (p < 0.05 at 1.0 microgram/ml mafosfamide by IL-3 and GM-CSF and p < 0.05 at 10 micrograms/ml mafosfamide by GM-CSF).	mafosfamide	42-53	interleukin 3	Homo sapiens	140-144
7688839-7	1993	A moderate but significant enhancement of mafosfamide cytotoxicity by HGF was also observed (p < 0.05 at 1.0 microgram/ml mafosfamide by IL-3 and GM-CSF and p < 0.05 at 10 micrograms/ml mafosfamide by GM-CSF).	mafosfamide	42-53	colony stimulating factor 2	Homo sapiens	149-155
8424816-1	1993	Several murine aldehyde dehydrogenases, most notably AHD-2, are known to catalyze the detoxification of cyclophosphamide, mafosfamide, and other oxazaphosphorines.	mafosfamide	122-133	aldehyde dehydrogenase family 1, subfamily A1	Mus musculus	53-58
8424816-7	1993	In ex vivo experiments, chloral hydrate markedly potentiated the antitumor activity of mafosfamide against oxazaphosphorine-resistant L1210/OAP and P388/CLA cells.	mafosfamide	87-98	selectin P ligand	Homo sapiens	153-156
8137996-6	1993	The CD34+ cells isolated form CML-BC and CML-CP patients were also more susceptible to mafosfamide cytotoxicity in comparison to CD34+ cells derived from NBMC.	mafosfamide	87-98	CD34 molecule	Homo sapiens	4-8
1515637-7	1992	Patients transplanted with marrow purged by mafosfamide also recovered earlier when treated with rhu GM-CSF (16 v 20.5 days, P = .013).	mafosfamide	44-55	colony stimulating factor 2	Homo sapiens	101-107
2093359-0	1990	[Potentiation of the antiblastic activity of mafosfamide by GM-CSF and interleukin-3: a possible use in the treatment of acute myeloblastic leukemia].	mafosfamide	45-56	colony stimulating factor 2	Homo sapiens	60-66
1756324-6	1991	In contrast, 6/15 cases showed a significant increase in the mean (+/- SD) percentage of Ph1-negative metaphases in response to rGM-CSF (46 +/- 26, p less than or equal to 0.05), mafosfamide incubation (53 +/- 12, p less than or equal to 0.01), and the combination of mafosfamide incubation plus rGM-CSF (63 +/- 29, p less than or equal to 0.025).	mafosfamide	268-279	alanine--glyoxylate and serine--pyruvate aminotransferase	Homo sapiens	89-92
1756324-6	1991	In contrast, 6/15 cases showed a significant increase in the mean (+/- SD) percentage of Ph1-negative metaphases in response to rGM-CSF (46 +/- 26, p less than or equal to 0.05), mafosfamide incubation (53 +/- 12, p less than or equal to 0.01), and the combination of mafosfamide incubation plus rGM-CSF (63 +/- 29, p less than or equal to 0.025).	mafosfamide	268-279	colony stimulating factor 2	Rattus norvegicus	128-135
2048565-10	1991	(b) In Paris, St-Antoine, using TBI and marrow purged with mafosfamide at levels individually adjusted (Blood 1986;67:1367), the probability of remission and DFS were 84 and 62% in AML CR1 63 and 59% in ALL CR1, respectively.	mafosfamide	59-70	complement C3b/C4b receptor 1 (Knops blood group)	Homo sapiens	185-188
2093359-0	1990	[Potentiation of the antiblastic activity of mafosfamide by GM-CSF and interleukin-3: a possible use in the treatment of acute myeloblastic leukemia].	mafosfamide	45-56	interleukin 3	Homo sapiens	71-84
2093359-5	1990	The sensitivity of leukemic cells preincubated with GM-CSF and IL-3 to the cytotoxic action of mafosfamide was greater than that of the control cells treated with mafosfamide alone.	mafosfamide	95-106	colony stimulating factor 2	Homo sapiens	52-58
2093359-5	1990	The sensitivity of leukemic cells preincubated with GM-CSF and IL-3 to the cytotoxic action of mafosfamide was greater than that of the control cells treated with mafosfamide alone.	mafosfamide	95-106	interleukin 3	Homo sapiens	63-67
2093359-5	1990	The sensitivity of leukemic cells preincubated with GM-CSF and IL-3 to the cytotoxic action of mafosfamide was greater than that of the control cells treated with mafosfamide alone.	mafosfamide	163-174	colony stimulating factor 2	Homo sapiens	52-58
2093359-5	1990	The sensitivity of leukemic cells preincubated with GM-CSF and IL-3 to the cytotoxic action of mafosfamide was greater than that of the control cells treated with mafosfamide alone.	mafosfamide	163-174	interleukin 3	Homo sapiens	63-67
2182739-3	1990	In particular, we show data concerning: 1) the use of interleukin 3, granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin 1 to expand hematopoietic progenitor cell growth in the early phase of ABMT; 2) in vitro marrow purging with Mafosfamide and GM-CSF in chronic myelogenous leukemia; and 3) growth requirements of MY10-derived leukemic colony-forming units.	mafosfamide	252-263	interleukin 1 alpha	Homo sapiens	131-144
2606575-1	1989	The sensitivity of a cyclophosphamide (CP)-resistant MIR rat mammary carcinoma cell variant (MIRCPr) in monolayer culture towards the cytotoxic effect of mafosfamide (an analogue of "activated" CP) was measured as a function of extracellular pH (pHe).	mafosfamide	154-165	membrane associated ring-CH-type finger 8	Rattus norvegicus	53-56
2606575-4	1989	At pHe 6.2, however, this value was reduced to 3 X 10(-4), i.e., a value equal to that for the CP-sensitive parental MIR cells exposed to the same concentration of mafosfamide at pHe 7.4.	mafosfamide	164-175	membrane associated ring-CH-type finger 8	Rattus norvegicus	117-120
3500254-4	1987	In vitro studies of the direct effects of CY metabolites (mafosfamide and 4-hydroperoxycyclophosphamide) on human monocytes showed only concomitant decreases in production of IL-1 and TNF-like molecules.	mafosfamide	58-69	interleukin 1 alpha	Homo sapiens	175-179
2676042-5	1989	BM cells previously treated in vitro with mafosfamide (ASTA-Z) under conditions identical to those used in the purging of autologous BM grafts, also demonstrated an enhanced cumulative response to combinations of GM-CSF and IL-3, with up to 100-fold increase in CFU-GM as compared with controls (p less than 0.001).	mafosfamide	42-53	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	213-219
2676042-5	1989	BM cells previously treated in vitro with mafosfamide (ASTA-Z) under conditions identical to those used in the purging of autologous BM grafts, also demonstrated an enhanced cumulative response to combinations of GM-CSF and IL-3, with up to 100-fold increase in CFU-GM as compared with controls (p less than 0.001).	mafosfamide	42-53	interleukin 3	Mus musculus	224-228
2720708-1	1989	The influence of cis-4-sulfoethylthio-cyclophosphamide (mafosfamide) on natural killer cell activity was examined in vitro in order further to elucidate the possible immunological mechanisms of tumor regressions following low-dose oxazaphosphorine therapy.	mafosfamide	56-67	suppressor of cytokine signaling 6	Homo sapiens	17-22
3181395-3	1988	We conclude that, in classical cases of Ph1-positive CML, Mafosfamide purging of bone marrow will not be effective.	mafosfamide	58-69	alanine--glyoxylate and serine--pyruvate aminotransferase	Homo sapiens	40-43
3500254-4	1987	In vitro studies of the direct effects of CY metabolites (mafosfamide and 4-hydroperoxycyclophosphamide) on human monocytes showed only concomitant decreases in production of IL-1 and TNF-like molecules.	mafosfamide	58-69	tumor necrosis factor	Homo sapiens	184-187
29749441-4	2018	The second aim was to evaluate the abilities of fludarabine (FDR) and mafosfamide (MFA; a metabolite of cyclophosphamide) to induce apoptosis of CD19-CAR-T cells via the use of Annexin V/propidium iodide double staining.	mafosfamide	70-81	CD19 molecule	Homo sapiens	145-149
3320579-3	1987	AML-CFC were significantly less sensitive than normal GM-CFC to mafosfamide at the doses commonly used to purge bone marrow autografts.	mafosfamide	64-75	tubulin folding cofactor C	Homo sapiens	4-7
33788715-0	2021	The Impact of Insulin on Low-dose Metronomic Vinorelbine and Mafosfamide in Breast Cancer Cells.	mafosfamide	61-72	insulin	Homo sapiens	14-21
33788715-3	2021	We investigated the impact of insulin on low-dose metronomic vinorelbine and mafosfamide in BC cell lines.	mafosfamide	77-88	insulin	Homo sapiens	30-37
33788715-6	2021	RESULTS: Insulin, especially at a concentration of 10 mug/ml, seemed to increase viability of vinorelbine-treated hormone receptor-positive BC cells, whereas low-dose mafosfamide treatment tended to be potentiated by insulin in triple-negative cells.	mafosfamide	167-178	insulin	Homo sapiens	217-224
29749441-4	2018	The second aim was to evaluate the abilities of fludarabine (FDR) and mafosfamide (MFA; a metabolite of cyclophosphamide) to induce apoptosis of CD19-CAR-T cells via the use of Annexin V/propidium iodide double staining.	mafosfamide	70-81	nuclear receptor subfamily 1 group I member 3	Homo sapiens	150-153
29749441-4	2018	The second aim was to evaluate the abilities of fludarabine (FDR) and mafosfamide (MFA; a metabolite of cyclophosphamide) to induce apoptosis of CD19-CAR-T cells via the use of Annexin V/propidium iodide double staining.	mafosfamide	70-81	annexin A5	Homo sapiens	177-186
29749441-4	2018	The second aim was to evaluate the abilities of fludarabine (FDR) and mafosfamide (MFA; a metabolite of cyclophosphamide) to induce apoptosis of CD19-CAR-T cells via the use of Annexin V/propidium iodide double staining.	mafosfamide	83-86	CD19 molecule	Homo sapiens	145-149
29749441-4	2018	The second aim was to evaluate the abilities of fludarabine (FDR) and mafosfamide (MFA; a metabolite of cyclophosphamide) to induce apoptosis of CD19-CAR-T cells via the use of Annexin V/propidium iodide double staining.	mafosfamide	83-86	nuclear receptor subfamily 1 group I member 3	Homo sapiens	150-153
29749441-4	2018	The second aim was to evaluate the abilities of fludarabine (FDR) and mafosfamide (MFA; a metabolite of cyclophosphamide) to induce apoptosis of CD19-CAR-T cells via the use of Annexin V/propidium iodide double staining.	mafosfamide	83-86	annexin A5	Homo sapiens	177-186